Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro. - Wikidata - wikimedia - TriplyDB

Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.

Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.

http://www.wikidata.org/entity/Q34451930

about

Comprehensive N-Glycan Profiling of Avian Immunoglobulin Y.Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells.Profiling N-linked oligosaccharides from IgG by high-performance anion-exchange chromatography with pulsed amperometric detection.

P2860

Q36085843-4691EBC4-2099-47BF-A526-D26E548D9AE1 Q38957458-5A0A8420-3A20-4F5A-9100-DC4929CB965B Q42290751-5E33D1E2-8605-40CF-A1C6-D66BBB046683 Q46608396-80125033-F71F-416C-A30B-C0D90BF32CD2

P2860

Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.

http://www.wikidata.org/entity/Q34451930

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Function characterization of a ...... l antibody cetuximab in vitro.

@ast

Function characterization of a ...... l antibody cetuximab in vitro.

@en

Function characterization of a ...... l antibody cetuximab in vitro.

@nl

type

label

Function characterization of a ...... l antibody cetuximab in vitro.

@ast

Function characterization of a ...... l antibody cetuximab in vitro.

@en

Function characterization of a ...... l antibody cetuximab in vitro.

@nl

prefLabel

Function characterization of a ...... l antibody cetuximab in vitro.

@ast

Function characterization of a ...... l antibody cetuximab in vitro.

@en

Function characterization of a ...... l antibody cetuximab in vitro.

@nl

P1433

Q34451930-662323E4-29A0-4991-BCD2-E8A52FCDC7D7

P1476

Q34451930-0429934B-5474-4622-A5F9-06D1E4E72281

P2093

Q34451930-30FD1460-36B8-4E44-B6D4-DE4380FFE66F

Q34451930-838BAEEF-C8D3-4CC5-ACE3-88A00C93525E

Q34451930-9CC23199-B219-46C8-BDD6-3374591DB913

Q34451930-9F55FF2E-1A81-4973-9FD8-C7BBBDB7685E

Q34451930-BD319220-DE3B-40E4-8296-CB637E8AAEF5

Q34451930-C2C784E8-E451-4D43-8103-6DC390AB934C

Q34451930-DFE7DD94-0AA2-4F6E-9D9C-154991173E37

Q34451930-E96F60A1-D9B1-4347-8EB7-0734486E2C23

Q34451930-F1D96395-277E-4D3D-8E8F-BCEE6857D299

P2860

Q34451930-0737C527-3D00-4CB1-B563-4E4659DA1908

Q34451930-09483956-920A-4730-8A8B-B95FEA6F31F7

Q34451930-155A57BD-1876-47C0-9B31-3636D921F6D6

Q34451930-2375BB4D-3493-4773-B408-E66020242992

Q34451930-309083F7-C753-437E-AB93-7E93DF0701EE

Q34451930-32C57633-ECF4-4A8E-87F9-5A96758D45E4

Q34451930-36C9746B-0CBD-43A2-A9C8-BED5F8FED94C

Q34451930-496D18DD-FBC8-467F-AD35-A0CDE05CB88D

Q34451930-49AF7992-2E69-46B4-9F53-6D04BFC8A4AF

Q34451930-6A870196-4EBC-4933-ACBF-141612E15079

P2888

Q34451930-C754434E-51D2-45B8-9C3D-B2895E024FD2

P304

Q34451930-197A4856-2CA7-4939-9FA5-F163EDF3C907

P31

Q34451930-207BCD61-6C75-4657-BC93-2BA56D70E1B0

P356

Q34451930-8D9365E5-8FAB-42C2-8CE2-23F171C52CC8

P433

Q34451930-40540636-79AC-4D4A-AB1B-B470CC384F01

P478

Q34451930-4B55BC31-B268-45C7-BF9F-D8334D747DED

P577

Q34451930-16CB6013-9A2D-4FAE-BF3C-3A64EF4BD565

P5875

Q34451930-4CE26161-9106-4E1C-BD9A-727B8821E4C1

P6179

Q34451930-6319657B-FED1-4656-892E-20FED59F6C36

P698

Q34451930-2FBBD0BB-9FE9-4FFE-9F8D-B9A026503186

P921

Q34451930-3B9A1757-618E-4B82-A6F5-297CE2B0CEC3

P932

Q34451930-539C6F3E-0E5A-429D-8F8F-298386F92224

P356

P1433

Acta Pharmacologica Sinica

P1476

Function characterization of a ...... l antibody cetuximab in vitro.

@en

P2093

Can-ping Ruan

http://www.w3.org/2001/XMLSchema#string

Chang-hong Yi

http://www.w3.org/2001/XMLSchema#string

Chun-fang Gao

http://www.w3.org/2001/XMLSchema#string

Hao Wang

http://www.w3.org/2001/XMLSchema#string

Jun Ji

http://www.w3.org/2001/XMLSchema#string

Meng Fang

http://www.w3.org/2001/XMLSchema#string

Xin-yun Xu

http://www.w3.org/2001/XMLSchema#string

Xing Gu

http://www.w3.org/2001/XMLSchema#string

Yun-peng Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism.

Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models.

Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides.

Isolation of a cDNA encoding a murine UDPgalactose:beta-D-galactosyl- 1,4-N-acetyl-D-glucosaminide alpha-1,3-galactosyltransferase: expression cloning by gene transfer.

Glycosylation of recombinant antibody therapeutics.

P2888

P304

1439-1446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2014.77

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266263266

http://www.w3.org/2001/XMLSchema#string

P6179

1023740630

http://www.w3.org/2001/XMLSchema#string

P698

25263334

http://www.w3.org/2001/XMLSchema#string

P921

P932

4220073

http://www.w3.org/2001/XMLSchema#string